Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04929548 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jul 1, 2021 to Jan 5, 2022
    • Start date: Jul 1, 2021 to Jan 5, 2022
    v3
  2. Primary completion date: Jun 6, 2021 to Jul 1, 2021
    • Start date: Jun 6, 2021 to Jul 1, 2021
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a single-arm, single-center exploratory clinical study. Twenty patients with early-stage HER2-positive breast cancer are planned to be included, and the primary objective is to evaluate the efficacy of neoadjuvant regimen of Pyrotinib in combination with trastuzumab + pertuzumab.
Trial Details
NCT Number NCT04929548
Lead Sponsor Wuhan University
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov